EUVIMEDEUVIMED entdecken
Crossref

Anthraquinones extracted from Rubia cordifolia Linn as potential ligands to treat Alzheimer’s disease

Pottella Srinivasulu, Janga Ramesh Babu, T.N.V. Ganesh Kumar, Padarthi Pavan Kumar, S. Vidyadhara

The Thai Journal of Pharmaceutical Sciences · 01.01.2021 · 45 (3) · 178-186

DOI: 10.56808/3027-7922.2488 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Thai Journal of Pharmaceutical Sciences, online erschienen am 01.01.2021. Verfasst von Pottella Srinivasulu und 4 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The present investigation aims to predict the pharmacokinetic aspects and assessing the anti-Alzheimer’s activity using both molecular docking platform and ex vivo pharmacological studies on muscle contraction. Materials and Methods: 2-Methyl Anthraquinone (MAQ) and Quinizarine (QNZ) were isolated from Rubia cordifolia L., and evaluated for absorption, distribution, metabolism, excretion, and toxicity. Molecular docking was performed with the help of Mcule software on five drug targets acetylcholinesterase enzyme (AChE), cyclin-dependent kinase5 (CDK5), glycogen synthase kinase 3β (GSK3β), monoamine oxidase (MAO-B), and β-secretase enzyme (BACE). The pharmacological activity was screened by recording the muscle contractions of chick ileum.

Results

The selected compounds were following Lipinski rule of five and the in silico studies have shown that the compounds possess drug likeliness, appreciated absorption, distribution, admired bioavailability, acceptable toxicity profile, and ability to cross the blood-brain barrier. The multi-target screening of AChE, CDK5, MAOB, GSK3β, and BACE for MAQ and QNZ showed greater binding energy of −9.9, −10, −10.5, −9.4, and 8.2 kcal/mol and −9.6, −9.1, −9.9, −8.9, and 7.8 kcal/mol, respectively. The ex vivo studies have shown to possess synergistic effect in increasing the muscle contractility response of MAQ and QNZ with acetylcholine.

Conclusion

The in silico parameters have shown good pharmacokinetic profile of the isolated compounds. The binding energy and affinity of amino acids with ligands have similar behavior in the ex vivo studies. It is suggested that the isolated compounds have promising anti-Alzheimer’s activity. Further studies are required to confirm the possibility of anti-Alzheimer’s activity of the selected compounds.

Zitieren

APA

Srinivasulu, P., Babu, J. R., Kumar, T. G., Kumar, P. P., & Vidyadhara, S. (2021). Anthraquinones extracted from Rubia cordifolia Linn as potential ligands to treat Alzheimer’s disease. The Thai Journal of Pharmaceutical Sciences, 45(3), 178-186. https://doi.org/10.56808/3027-7922.2488

Vancouver

Srinivasulu P, Babu JR, Kumar TG, Kumar PP, Vidyadhara S. Anthraquinones extracted from Rubia cordifolia Linn as potential ligands to treat Alzheimer’s disease. The Thai Journal of Pharmaceutical Sciences. 2021;45(3):178-186. doi:10.56808/3027-7922.2488

BibTeX
@article{Srinivasulu2021,
  author = {Srinivasulu, Pottella and Babu, Janga Ramesh and Kumar, T.N.V. Ganesh and Kumar, Padarthi Pavan and Vidyadhara, S.},
  title = {Anthraquinones extracted from Rubia cordifolia Linn as potential ligands to treat Alzheimer’s disease},
  journal = {The Thai Journal of Pharmaceutical Sciences},
  year = {2021},
  volume = {45},
  number = {3},
  pages = {178--186},
  doi = {10.56808/3027-7922.2488}
}
Kostenlos starten →